Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00626366|
Recruitment Status : Unknown
Verified February 2008 by University of Nebraska.
Recruitment status was: Not yet recruiting
First Posted : February 29, 2008
Last Update Posted : February 29, 2008
|Condition or disease||Intervention/treatment|
|Chronic Sinusitis||Radiation: Sinus CT Scan Drug: Omnipaque 240 Contrast Solution Drug: Omnipaque 240 mg I/mL|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||8 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison|
|Study Start Date :||March 2008|
|Estimated Primary Completion Date :||April 2008|
|Estimated Study Completion Date :||June 2008|
This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.
Radiation: Sinus CT Scan
Subjects will undergo a Xoran miniCAT scan of their sinusesDrug: Omnipaque 240 Contrast Solution
Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.
Radiation: Sinus CT Scan
Subjects will undergo a Xoran miniCAT scan of their sinusesDrug: Omnipaque 240 mg I/mL
Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
- To determine the distribution of nasal sprays and drops. [ Time Frame: 2 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00626366
|Contact: Kelli L Olechoski, BAfirstname.lastname@example.org|
|Contact: Erin K O'Brien, MDemail@example.com|
|United States, Nebraska|
|ENT Specialist PC of Omaha||Not yet recruiting|
|Omaha, Nebraska, United States, 68114|
|Contact: Kelli L Olechoski, BA 402-689-0767 firstname.lastname@example.org|
|Principal Investigator:||Erin K O'Brien, MD||UNMC Department of Otolaryngology|
|Study Chair:||Donald Leopold, MD||UNMC Department of Otolaryngology|